|
WO2021081058A1
|
|
Compositions, methods and uses of messenger rna
|
|
WO2021072172A1
|
|
Compositions, methods and uses of messenger rna
|
|
WO2021055609A1
|
|
Mrna encoding engineered cftr
|
|
WO2021021988A1
|
|
Treatment of cystic fibrosis by delivery of nebulized mrna encoding cftr
|
|
WO2021016430A1
|
|
Stable compositions of mrna-loaded lipid nanoparticles and processes of making
|
|
WO2021007278A1
|
|
Improved mrna-loaded lipid nanoparticles and processes of making the same
|
|
WO2020257716A1
|
|
Tricine and citric acid lipids
|
|
WO2020257611A1
|
|
Cationic lipids comprising an hydroxy moiety
|
|
WO2020243540A1
|
|
Macrocyclic lipids
|
|
WO2020232371A1
|
|
Methods for purification of messenger rna
|
|
WO2020232276A1
|
|
Improved process of preparing mrna-loaded lipid nanoparticles
|
|
WO2020227085A1
|
|
Di-thioester cationic lipids
|
|
WO2020219427A1
|
|
Thioester cationic lipids
|
|
WO2020214946A1
|
|
Cystine cationic lipids
|
|
WO2020146344A1
|
|
Composition and methods for treatment of primary ciliary dyskinesia
|
|
WO2020106946A1
|
|
TREATMENT OF CYSTIC FIBROSIS BY DELIVERY OF NEBULIZED mRNA ENCODING CFTR
|
|
WO2020106903A1
|
|
Cationic lipid compounds and compositions thereof for use in the delivery of messenger rna
|
|
WO2020102172A2
|
|
Methods for inducing immune tolerance
|
|
WO2020097511A2
|
|
Messenger rna therapy for treatment of ocular diseases
|
|
CA3115119A1
|
|
Methods and compositions for messenger rna purification
|
